FVB;129P2-Brca2tm1Brn/Cnrm

Status

Available to order

EMMA IDEM:01642
Citation informationRRID:IMSR_EM:01642 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameFVB;129P2-Brca2tm1Brn/Cnrm
Alternative nameBr2F
Strain typeTargeted Mutant Strains : Conditional mutation
Allele/Transgene symbolBrca2tm1Brn
Gene/Transgene symbolBrca2

Information from provider

ProviderAnton Berns
Provider affiliationResearch - Animal Facility, The Netherlands Cancer Institute
Genetic informationInsertion of loxP sequences at the 5' and 3' of exon 11 in Brca2 gene.
Phenotypic informationConditional Brca2 knock-out; no phenotype.
References
  • Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.;Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A, ;2001;Nature genetics;29;418-25; 11694875

Information from EMMA

Archiving centreCNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (gene matching)
  • abnormal rib morphology / MGI
  • abnormal sternum morphology / MGI
  • decreased bone marrow cell number / MGI
  • kinked tail / MGI
  • abnormal branching of the mammary ductal tree / MGI
  • spleen hypoplasia / MGI
  • open neural tube / MGI
  • small ovary / MGI
  • small testis / MGI
  • abnormal epidermal layer morphology / MGI
  • abnormal epidermis stratum basale morphology / MGI
  • abnormal epidermis stratum spinosum morphology / MGI
  • absent epidermis stratum corneum / MGI
  • decreased body weight / MGI
  • impaired hematopoiesis / MGI
  • abnormal embryo development / MGI
  • decreased embryo size / MGI
  • abnormal visceral yolk sac morphology / MGI
  • male infertility / MGI
  • female infertility / MGI
  • neoplasm / MGI
  • increased tumor incidence / MGI
  • increased T cell derived lymphoma incidence / MGI
  • increased carcinoma incidence / MGI
  • decreased tumor incidence / MGI
  • abnormal skin morphology / MGI
  • abnormal motor capabilities/coordination/movement / MGI
  • premature death / MGI
  • abnormal developmental patterning / MGI
  • abnormal embryonic tissue morphology / MGI
  • abnormal extraembryonic tissue morphology / MGI
  • abnormal axial skeleton morphology / MGI
  • no abnormal phenotype detected / MGI
  • abnormal hematopoietic system morphology/development / MGI
  • absent ovarian follicles / MGI
  • abnormal chromosome morphology / MGI
  • embryonic growth retardation / MGI
  • increased mortality induced by ionizing radiation / MGI
  • abnormal mitosis / MGI
  • fetal growth retardation / MGI
  • decreased incidence of tumors by chemical induction / MGI
  • enlarged allantois / MGI
  • absent germ cells / MGI
  • increased thymus weight / MGI
  • abnormal amnion morphology / MGI
  • sepsis / MGI
  • azoospermia / MGI
  • growth/size/body region phenotype / MGI
  • reproductive system phenotype / MGI
  • abnormal cell physiology / MGI
  • increased apoptosis / MGI
  • early cellular replicative senescence / MGI
  • abnormal DNA repair / MGI
  • decreased survivor rate / MGI
  • decreased common myeloid progenitor cell number / MGI
  • chromosomal instability / MGI
  • increased sensitivity to induced cell death / MGI
  • adrenal gland hyperplasia / MGI
  • decreased fetal weight / MGI
  • decreased birth weight / MGI
  • increased mammary gland tumor incidence / MGI
  • decreased tumor latency / MGI
  • abnormal double-strand DNA break repair / MGI
  • postnatal lethality, incomplete penetrance / MGI
  • neonatal lethality, incomplete penetrance / MGI
  • perinatal lethality, incomplete penetrance / MGI
  • prenatal lethality, complete penetrance / MGI
  • embryonic lethality, complete penetrance / MGI
  • embryonic lethality between somite formation and embryo turning, complete penetrance / MGI
  • embryonic lethality during organogenesis, complete penetrance / MGI
  • prenatal lethality, incomplete penetrance / MGI
  • embryonic lethality during organogenesis, incomplete penetrance / MGI
  • lethality throughout fetal growth and development, incomplete penetrance / MGI
  • abnormal proamniotic cavity morphology / MGI
  • decreased fibroblast proliferation / MGI
  • increased lymphoma incidence / MGI
  • ovary degeneration / MGI

Literature references

  • Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.;Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A, ;2001;Nature genetics;29;418-25; 11694875

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).